Sentences with phrase «current stage of their disease»

Not exact matches

Our goal is to complement the current strategic interest of Chiesi Farmaceutici in the space of rare diseases by investing in early stage opportunities and accelerate the expansion of the Chiesi network in the US among universities, venture capital investors, rare disease patient organizations and start - ups developing treatments for rare diseases.

«Unfortunately, the current standard laboratory test is often unable to detect Lyme disease at an early stage of the infection,» explains Hannes Stockinger, Head of the Institute for Hygiene and Applied Immunology of the Center for Pathophysiology, Infectionology and Immunology of MedUni Vienna.

Electrophysiological testing to measure peripheral nerve conduction properties is not a viable alternative because current methods lack the sensitivity required to detect damage to small, unmyelinated fibers, especially in early stages of disease.

In the current study, deploying TFPI and an isoform of tenascin C, TNC - FN IIIC, with CA 19 - 9 improved performance discriminating stage I and II disease from healthy or benign disease controls.

Adding two blood - borne proteins associated with cancer cell migration increases the predictive ability of the current biomarker for pancreatic cancer to detect early stage disease, a research team from The University of Texas MD Anderson Cancer Center reports in the Journal of the National Cancer Institute.

The current study enrolled 161 participants — 100 with end - stage kidney disease, all of whom were dialysis dependent; 36 with chronic disease not yet at the end stage, and 25 healthy controls.

Properly diagnosing Lyme disease can at times be challenging because of the limitations of the current laboratory test, particularly during the early stages of disease.

The only current treatment for end - stage liver disease is a liver transplant, and the number of livers available from deceased donors is limited.

So clinical trials are certainly something that are still far away at the current stage, but it is certainly worthwhile to follow our experimental approach both in vitro and in vivo, in order to test whether at some stage we can really move forward and test, whether by reprogramming endogenous cells, we can reconstitute neural circuits that are damaged or deceased; and, thereby also improve the lives of many people that suffer neurological diseases.

Table 1: Selection, Design & Construction of HSV - based Oncolytic Viruses Table 2: Selection, Design & Construction of Adenovirus - based Oncolytic Viruses Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisitions

But there's another group of PD symptoms, termed the «non-motor symptoms» (NMS) of PD, that gets far less attention, even though NMS begin to manifest earlier in the disease, are harder to treat with current therapies, and include some of the most crippling features of living with the later stages of PD.

The current project utilized an array of immunochemical and molecular tools to perform a characterization of retinal pathology in the early stages of disease progression using a well - validated mouse model of AD (APPSWE / PS1ΔE 9).

It's life cycle involves an egg which develops into larval stage (6 weeks feeds on rodents and birds), then nymph (8 weeks this is believed to be the cause of Lyme disease in people also feeds on other mammals), then adult tick (current belief is that this is the cause of Lyme in the dog and feeds on other mammals).

Medical experts have noted that patients in the early stages of chronic kidney disease are at increased risk for clinical depression according to the study in the current issue of the American Journal of Kidney Diseases.